Immutep halted its phase III TACTI‑004 trial of eftilagimod alfa (IMP‑321, efti) in first‑line non‑small‑cell lung cancer after an independent data monitoring committee recommended stopping for futility. The decision triggered an immediate market reaction and leaves the LAG‑3 therapeutic strategy facing fresh scrutiny. The company said it is analyzing the data to understand the discrepancy between earlier positive signals and the interim read. The discontinuation forced a near‑term liquidity and valuation shock for Immutep and will shape investor and partner approaches to LAG‑3–targeting immunotherapies. Sources: company statements, independent data monitoring committee findings and market filings.